Dianthus Therapeutics (DNTH) Competitors $18.10 -0.65 (-3.44%) Closing price 03:59 PM EasternExtended Trading$18.12 +0.02 (+0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. AAPG, NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, and GMTXShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Ascentage Pharma Group International NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Ascentage Pharma Group International (NASDAQ:AAPG) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Do insiders and institutionals have more ownership in AAPG or DNTH? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate AAPG or DNTH? Dianthus Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 196.09%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has preferable valuation & earnings, AAPG or DNTH? Ascentage Pharma Group International has higher revenue and earnings than Dianthus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$980.65M2.68N/AN/AN/ADianthus Therapeutics$6.52M88.24-$43.56M-$2.88-6.22 Does the MarketBeat Community prefer AAPG or DNTH? Dianthus Therapeutics received 27 more outperform votes than Ascentage Pharma Group International when rated by MarketBeat users. However, 100.00% of users gave Ascentage Pharma Group International an outperform vote while only 93.33% of users gave Dianthus Therapeutics an outperform vote. CompanyUnderperformOutperformAscentage Pharma Group InternationalOutperform Votes1100.00% Underperform VotesNo VotesDianthus TherapeuticsOutperform Votes2893.33% Underperform Votes26.67% Is AAPG or DNTH more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Ascentage Pharma Group International's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the media refer more to AAPG or DNTH? In the previous week, Dianthus Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 4 mentions for Dianthus Therapeutics and 3 mentions for Ascentage Pharma Group International. Dianthus Therapeutics' average media sentiment score of 1.30 beat Ascentage Pharma Group International's score of 0.63 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDianthus Therapeutics beats Ascentage Pharma Group International on 10 of the 15 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$580.52M$6.88B$5.60B$8.63BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-7.228.9127.3220.13Price / Sales88.24259.84411.80160.09Price / CashN/A65.8538.2534.64Price / Book1.576.637.154.74Net Income-$43.56M$143.71M$3.23B$247.80M7 Day Performance-0.33%4.74%3.47%2.70%1 Month Performance-8.63%15.14%12.95%10.03%1 Year Performance-25.29%5.93%32.16%15.42% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.3698 of 5 stars$18.11-3.4%$53.00+192.7%-12.6%$582.26M$6.52M-7.2480Positive NewsAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600Positive NewsNAMSNewAmsterdam Pharma2.6265 of 5 stars$18.93+4.5%$43.00+127.2%+11.0%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.2186 of 5 stars$65.02+0.2%$96.67+48.7%+24.8%$2.07BN/A-58.5810Analyst RevisionHRMYHarmony Biosciences4.956 of 5 stars$35.56+3.1%$53.00+49.0%+19.8%$2.04B$744.85M16.85200Positive NewsAnalyst RevisionKNSAKiniksa Pharmaceuticals2.9937 of 5 stars$27.92+2.0%$38.80+39.0%+54.9%$2.04B$481.17M-199.41220VCELVericel3.201 of 5 stars$40.46-2.0%$61.14+51.1%+5.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3576 of 5 stars$13.96+5.4%$33.71+141.5%-27.4%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.4384 of 5 stars$26.59+3.8%$58.22+119.0%-22.0%$2.03B$662,000.00-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.8042 of 5 stars$31.74+67.5%$65.00+104.8%-42.0%$2.02BN/A-12.1640Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+31.4%$2.02BN/A-46.6830High Trading Volume Related Companies and Tools Related Companies Ascentage Pharma Group International Alternatives NewAmsterdam Pharma Alternatives Belite Bio Alternatives Harmony Biosciences Alternatives Kiniksa Pharmaceuticals Alternatives Vericel Alternatives Denali Therapeutics Alternatives CG Oncology Alternatives Vera Therapeutics Alternatives Gemini Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
